APA (7th ed.) Citation

Mahy, P., de Bast, M., Leveque, P. H., Gillart, J., Labar, D., Marchand, J., & Gregoire, V. (2004). Preclinical validation of the hypoxia tracer 2-(2-nitroimidazol-1-yl)-N-(3,3,3-[18F]trifluoropropyl)acetamide, [18F]EF3. European Journal of Nuclear Medicine & Molecular Imaging, 31(9), 1263. https://doi.org/10.1007/s00259-004-1573-2

Chicago Style (17th ed.) Citation

Mahy, P., M. de Bast, P. H. Leveque, J. Gillart, D. Labar, J. Marchand, and V. Gregoire. "Preclinical Validation of the Hypoxia Tracer 2-(2-nitroimidazol-1-yl)-N-(3,3,3-[18F]trifluoropropyl)acetamide, [18F]EF3." European Journal of Nuclear Medicine & Molecular Imaging 31, no. 9 (2004): 1263. https://doi.org/10.1007/s00259-004-1573-2.

MLA (9th ed.) Citation

Mahy, P., et al. "Preclinical Validation of the Hypoxia Tracer 2-(2-nitroimidazol-1-yl)-N-(3,3,3-[18F]trifluoropropyl)acetamide, [18F]EF3." European Journal of Nuclear Medicine & Molecular Imaging, vol. 31, no. 9, 2004, p. 1263, https://doi.org/10.1007/s00259-004-1573-2.